Literature DB >> 17698622

2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities.

Boris Rodenko1, Alida M van der Burg, Martin J Wanner, Marcel Kaiser, Reto Brun, Matthew Gould, Harry P de Koning, Gerrit-Jan Koomen.   

Abstract

A library of 2,N(6)-disubstituted adenosine analogs was synthesized and the analogs were tested for their antiprotozoal activities. It was found that 2-methoxy and 2-histamino and N(6)-m-iodobenzyl substitutions generally produced analogs with low levels of antiprotozoal activity. The best antiplasmodial activity was achieved with large aromatic substitutions, such as N(6)-2,2-diphenylethyl and naphthylmethyl, which could indicate a mechanism of action through aromatic stacking with heme in the digestive vacuole of Plasmodium spp. The activities against Trypanosoma cruzi trypomastigotes and Leishmania donovani amastigotes were generally low; but several analogs, particularly those with cyclopentylamino substitutions, displayed potent activities against Trypanosoma brucei rhodesiense and T. b. brucei bloodstream forms in vitro. The most active were 2-cyclopentylamino-N(6)-cyclopentyladenosine (compound NA42) and 2-cyclopentylamino-N(6)-cyclopentyladenine (compound NA134), with the nucleobase an order of magnitude more potent than the nucleoside, at 26 +/- 4 nM. It was determined that the mode of action of these purines was trypanostatic, with the compounds becoming trypanocidal only at much higher concentrations. Those 2,N(6)-disubstituted purines tested for their effects on purine transport in T. b. brucei displayed at best a moderate affinity for the transporters. It is highly probable that the large hydrophobic substitutions, which bestow high calculated octanol-water coefficient values on the analogs, allow them to diffuse across the membrane. Consistent with this view, the analogs were as effective against a T. b. brucei strain lacking the P2 nucleoside transporter as they were against the parental strain. As the analogs were not toxic to human cell lines, the purine analogs are likely to act on a trypanosome-specific target.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17698622      PMCID: PMC2151466          DOI: 10.1128/AAC.00425-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

Review 1.  Transporters in African trypanosomes: role in drug action and resistance.

Authors:  H P de Koning
Journal:  Int J Parasitol       Date:  2001-05-01       Impact factor: 3.981

2.  Structure-activity relationships and inhibitory effects of various purine derivatives on the in vitro growth of Plasmodium falciparum.

Authors:  L Harmse; R van Zyl; N Gray; P Schultz; S Leclerc; L Meijer; C Doerig; I Havlik
Journal:  Biochem Pharmacol       Date:  2001-08-01       Impact factor: 5.858

3.  Diamidine compounds: selective uptake and targeting in Plasmodium falciparum.

Authors:  A M Stead; P G Bray; I G Edwards; H P DeKoning; B C Elford; P A Stocks; S A Ward
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

4.  Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design.

Authors:  J C Bressi; C L Verlinde; A M Aronov; M L Shaw; S S Shin; L N Nguyen; S Suresh; F S Buckner; W C Van Voorhis; I D Kuntz; W G Hol; M H Gelb
Journal:  J Med Chem       Date:  2001-06-21       Impact factor: 7.446

5.  Adenosine transporters in bloodstream forms of Trypanosoma brucei brucei: substrate recognition motifs and affinity for trypanocidal drugs.

Authors:  H P de Koning; S M Jarvis
Journal:  Mol Pharmacol       Date:  1999-12       Impact factor: 4.436

6.  A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue.

Authors:  J Mikus; D Steverding
Journal:  Parasitol Int       Date:  2000-01       Impact factor: 2.230

7.  Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda.

Authors:  D Legros; S Evans; F Maiso; J C Enyaru; D Mbulamberi
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 Jul-Aug       Impact factor: 2.184

Review 8.  Glycolysis as a target for the design of new anti-trypanosome drugs.

Authors:  C L Verlinde; V Hannaert; C Blonski; M Willson; J J Périé; L A Fothergill-Gilmore; F R Opperdoes; M H Gelb; W G Hol; P A Michels
Journal:  Drug Resist Updat       Date:  2001-02       Impact factor: 18.500

9.  The phenomenon of treatment failures in Human African Trypanosomiasis.

Authors:  R Brun; R Schumacher; C Schmid; C Kunz; C Burri
Journal:  Trop Med Int Health       Date:  2001-11       Impact factor: 2.622

Review 10.  Monitoring drug resistance in leishmaniasis.

Authors:  S L Croft
Journal:  Trop Med Int Health       Date:  2001-11       Impact factor: 2.622

View more
  14 in total

1.  Symmetrical choline-derived dications display strong anti-kinetoplastid activity.

Authors:  Hasan M S Ibrahim; Mohammed I Al-Salabi; Nasser El Sabbagh; Neils B Quashie; Abdulsalam A M Alkhaldi; Roger Escale; Terry K Smith; Henri J Vial; Harry P de Koning
Journal:  J Antimicrob Chemother       Date:  2010-11-14       Impact factor: 5.790

2.  A new nonpolar N-hydroxy imidazoline lead compound with improved activity in a murine model of late-stage Trypanosoma brucei brucei infection is not cross-resistant with diamidines.

Authors:  Carlos H Ríos Martínez; Florence Miller; Kayathiri Ganeshamoorthy; Fabienne Glacial; Marcel Kaiser; Harry P de Koning; Anthonius A Eze; Laura Lagartera; Tomás Herraiz; Christophe Dardonville
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

3.  SAR Studies of Diphenyl Cationic Trypanocides: Superior Activity of Phosphonium over Ammonium Salts.

Authors:  Christophe Dardonville; Abdulsalam A M Alkhaldi; Harry P De Koning
Journal:  ACS Med Chem Lett       Date:  2014-12-10       Impact factor: 4.345

4.  Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis.

Authors:  Maya Berg; Linda Kohl; Pieter Van der Veken; Jurgen Joossens; Mohammed I Al-Salabi; Valeria Castagna; Francesca Giannese; Paul Cos; Wim Versées; Jan Steyaert; Philippe Grellier; Achiel Haemers; Massimo Degano; Louis Maes; Harry P de Koning; Koen Augustyns
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

5.  The Chemical Characterization of Nigerian Propolis samples and Their Activity Against Trypanosoma brucei.

Authors:  Ruwida Omar; John O Igoli; Tong Zhang; Alexander I Gray; Godwin U Ebiloma; Carol J Clements; James Fearnley; RuAngeli Edrada Ebel; Tim Paget; Harry P de Koning; David G Watson
Journal:  Sci Rep       Date:  2017-04-19       Impact factor: 4.379

6.  Antileishmanial and antitrypanosomal activity of symmetrical dibenzyl-substituted α,β-unsaturated carbonyl-based compounds.

Authors:  Abdulsalam Am Alkhaldi; Harry P de Koning; Syed Nasir Abbas Bukhari
Journal:  Drug Des Devel Ther       Date:  2019-04-24       Impact factor: 4.162

7.  Pyrimidine biosynthesis is not an essential function for Trypanosoma brucei bloodstream forms.

Authors:  Juma A M Ali; Daniel N A Tagoe; Jane C Munday; Anne Donachie; Liam J Morrison; Harry P de Koning
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

8.  Trypanosoma brucei adenine-phosphoribosyltransferases mediate adenine salvage and aminopurinol susceptibility but not adenine toxicity.

Authors:  Alexandra Lüscher; Estelle Lamprea-Burgunder; Fabrice E Graf; Harry P de Koning; Pascal Mäser
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2013-12-19       Impact factor: 4.077

9.  Targeting the parasite's DNA with methyltriazenyl purine analogs is a safe, selective, and efficacious antitrypanosomal strategy.

Authors:  Boris Rodenko; Martin J Wanner; Abdulsalam A M Alkhaldi; Godwin U Ebiloma; Rebecca L Barnes; Marcel Kaiser; Reto Brun; Richard McCulloch; Gerrit-Jan Koomen; Harry P de Koning
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

10.  Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma brucei.

Authors:  Isabel M Vincent; Darren J Creek; Karl Burgess; Debra J Woods; Richard J S Burchmore; Michael P Barrett
Journal:  PLoS Negl Trop Dis       Date:  2012-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.